[骨髓间充质干细胞在慢性髓性白血病对酪氨酸激酶抑制剂耐药中的作用——综述]
[Role of Bone Marrow Mesenchymal Stem Cells in Resistance of Chronic Myeloid Leukemia to Tyrosine Kinase Inhibitors -Review].
作者信息
Zhang Xiao-Yan, Wan Qian, Fang Li-Jun, Li Jian
机构信息
The Key Laboratory of Hematology of Jiangxi Province, The Second Affiliated Hospital of Nanchang University; Graduate School of Medicine; Basic Medical School, Nanchang University, Nanchang 330006, Jiangxi Province, China.
The Key Laboratory of Hematology of Jiangxi Province, The Second Affiliated Hospital of Nanchang University; Graduate School of Medicine,Nanchang 330006, Jiangxi Province, China.
出版信息
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Dec;24(6):1901-1904. doi: 10.7534/j.issn.1009-2137.2016.06.053.
Chronic myeloid leukemia (CML) is a disease originated from malignant hematopoietic stem cell disorder. In CML, mesenchymal stem cells(MSC) have been changed in the bone marrow microenvironment, which can protect the leukemia cells from apoptosis induced by tyrosine kinase inhibitors (TKI) and lead to the resistance to TKI by the secretion of soluble factors, involvement in cell-cell adhesion, and so on. This review mainly focuses on the changes of the bone marrow mesenchymal stem cells in CML, as well as the role and mechanism of MSC in the CML resistance of TKI. The concrete probrems dicussing in this review are role of MSC in bone marrow microenviroment, characteristics of MSC in CML, the related mechanisms of MSC in drug resistance and so on.
慢性髓性白血病（CML）是一种起源于恶性造血干细胞紊乱的疾病。在慢性髓性白血病中，骨髓微环境中的间充质干细胞（MSC）发生了变化，它可以保护白血病细胞免受酪氨酸激酶抑制剂（TKI）诱导的凋亡，并通过分泌可溶性因子、参与细胞间粘附等导致对TKI产生耐药性。本综述主要关注慢性髓性白血病中骨髓间充质干细胞的变化，以及间充质干细胞在慢性髓性白血病对TKI耐药中的作用和机制。本综述讨论的具体问题包括间充质干细胞在骨髓微环境中的作用、慢性髓性白血病中间充质干细胞的特征、间充质干细胞耐药的相关机制等。
Zotero 插件